Erratum: Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status (International Journal of Cancer (2016) 138:6 (1516-1527) DOI: 10.1002/ijc.29881);Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status

International Journal of Cancer

Volumn 138, Issue 6, 2016, Pages 1516-1527

  Kato, Junko ^a   Futamura, Manabu ^a   Kanematsu, Masako ^a   Gaowa, Siqin ^a   Mori, Ryutaro ^a   Tanahashi, Toshiyuki ^a   Matsuhashi, Nobuhisa ^a   Yoshida, Kazuhiro ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

cetuximab; colorectal cancer; k ras mutant; zoledronic acid

Indexed keywords

CASPASE 3; CETUXIMAB; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; IMIDAZOLE DERIVATIVE; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING; WILD TYPE; ANIMAL; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CETUXIMAB; COLORECTAL NEOPLASMS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; IMIDAZOLES; MALE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84954386382     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30045     Document Type: Erratum

References (42)

1. Parkin DM, Bray F, Ferlay J, et al., Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Center MM, Jemal A, Smith RA, et al., Worldwide variations in colorectal cancer. CA Cancer J Clin 2009; 59: 366-78.
3. Ducreux M, Bennouna J, Hebbar M, et al., Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 2011; 128: 682-90.
4. Schmoll HJ, Cartwright T, Tabernero J, et al., Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25: 102-9.
5. Alberts SR, Sargent DJ, Nair S, et al., Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012; 307: 1383-93.
6. Ocvirk J, Brodowicz T, Wrba F, et al., Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010; 16: 3133-43.
7. Saltz LB, Clarke S, Díaz-Rubio E, et al., Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-9.
8. Hurwitz H, Fehrenbacher L, Novotny W, et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
9. Ciardiello F, Tortora G., EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74.
10. Bang YJ, Van Cutsem E, Feyereislova A, et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97.
11. Slamon DJ, Leyland-Jones B, Shak S, et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al., Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
13. Terashima M, Kitada K, Ochiai A, et al., Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012; 18: 5992-6000.
14. Van Cutsem E, Köhne CH, Hitre E, et al., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.
15. Bokemeyer C, Bondarenko I, Makhson A, et al., Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-71.
16. Lièvre A, Bachet JB, Boige V, et al., KRAS mutations as independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-9.
17. Karapetis CS, Khambata-Ford S, Jonker DJ, et al., K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
18. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al., Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-8.
19. Hirsh V, Major PP, Lipton A, et al., Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008; 3: 228-36.
20. Chlebowski RT, Chen Z, Cauley JA, et al., Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010; 28: 3582-90.
21. Kuroda J, Kimura S, Segawa H, et al., The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 2003; 15: 2229-35.
22. Hiraga T, Williams PJ, Ueda A, et al., Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004; 10: 4559-67.
23. Corey E, Brown LG, Quinn JE, et al., Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003; 9: 295-306.
24. Tassone P, Tagliaferri P, Viscomi C, et al., Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003; 88: 1971-8.
25. Koizumi M, Nakaseko C, Ohwada C, et al., Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells. Eur J Haematol 2007; 79: 382-91.
26. Stathopoulos GT, Moschos C, Loutrari H, et al., Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med 2008; 178: 50-9.
27. Janakiraman M, Vakiani E, Zeng Z, et al., Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010; 70: 5901-11.
28. Miyamoto Y, Futamura M, Kitamura N, et al., Identification of UNC5A as a novel transcriptional target of tumor suppressor p53 and a regulator of apoptosis. Int J Oncol 2010; 36: 1253-60.
29. Kanematsu M, Futamura M, Takata M, et al., Clinical significance of glycoprotein non-metastatic B and its association with HER2 in breast cancer. Cancer Med 2015; 4: 1344-55.
30. Futamura M, Kamino H, Miyamoto Y, et al., Possible role of semaphorin 3F, a candidate tumor suppressor gene at 3p21.3, in p53-regulated tumor angiogenesis suppression. Cancer Res 2007; 67: 1451-60.
31. Moriceau G, Ory B, Mitrofan L, et al., Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res 2010; 70: 10329-39.
32. Reszka AA, Halasy-Nagy J, Rodan GA., Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001; 59: 193-202.
33. De Roock W, Jonker DJ, Di Nicolantonio F, et al., Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812-20.
34. Sato K, Yuasa T, Nogawa M, et al., A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer 2006; 95: 1354-61.
35. Slattery ML, Lundgreen A, Kadlubar SA, et al., JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol Carcinog 2013; 52: 155-66.
36. Niessner H, Beck D, Sinnberg T, et al., The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. J Invest Dermatol 2011; 131: 468-79.
37. Correal P, Marra M, Remondo C, et al., Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). Eur J Cancer 2010; 46: 1703-11.
38. Maniar A, Zhang X, Lin W, et al., Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 2010; 116: 1726-33.
39. Hortobagyi GN, Theriault RL, Porter L, et al., Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335: 1785-91.
40. Kanis JA, Powles T, Paterson AH, et al., Clodronate decreases the frequency of skeletal metastases in woman with breast cancer. Bone 1996; 19: 663-7.
41. Theriault RL, Lipton A, Hortobagyi GN, et al., Pamidronate reduces skeletal morbidity in woman with breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846-54.
42. Inoue K, Karashima T, Fukata S, et al., Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma. Clin Cancer Res 2005; 11: 6669-77.